Summary & Overview
HCPCS M1231: HCV Antibody Test, Nonreactive
HCPCS Level II code M1231 represents the administration and reporting of a hepatitis C virus (HCV) antibody test with a nonreactive result. This code is used to document laboratory-based serologic testing that indicates no detectable HCV antibodies at the time of testing. Nationally, accurate coding of HCV antibody results is important for public health surveillance, clinical follow-up decisions, and claims adjudication for preventive and diagnostic services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coding context, typical sites of service, and the clinical meaning of a nonreactive HCV antibody result. The publication outlines common billing practices, how the code fits into laboratory and outpatient service lines, and the implications for claims processing and documentation.
The content provides benchmarks and policy-relevant updates where available, clarifies clinical context for ordering and interpreting HCV antibody testing, and highlights areas where payers and providers commonly align or diverge on coverage and documentation expectations. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code M1231 describes a service in which a patient receives an HCV antibody test with a nonreactive result. The service type is clinical laboratory testing for hepatitis C virus (HCV) serology. The typical site of service is an outpatient laboratory or clinic setting where specimen collection and laboratory testing are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old adult presents to a primary care clinic for routine sexually transmitted infection screening after a recent high-risk exposure. The clinician orders a hepatitis C virus (HCV) antibody screening test. The patient has blood drawn on site and the laboratory performs an HCV antibody immunoassay. The result returns nonreactive, indicating no detectable HCV antibodies at the time of testing. The typical workflow includes patient registration and consent, specimen collection (venipuncture), specimen labeling and transport to the laboratory, assay run and result verification, and documentation of the nonreactive result in the electronic health record. Counseling is documented that the result is nonreactive and, depending on exposure timing and risk, recommendations for repeat testing or additional HCV RNA testing may be discussed and scheduled by clinic staff.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
23 | Unusual Anesthesia | Use if an unusual anesthesia circumstance is reported in conjunction with a procedure requiring anesthesia (rarely applicable to HCV antibody collection). |
52 | Reduced Services | Use when the specimen collection service is partially reduced or abbreviated. |